Publications

Hooda N, Suh M, Bylsma LC, Kelsh M. A systematic literature review of the association between dose reduction of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and survival in patients with HR-positive breast cancer (BC). Poster 1882eP, European Society for Medical Oncology (ESMO) Congress 2026, Madrid, Spain, October 23-27, 2026.

Bylsma L, Kelsh M, Jiang X, Mitchell M, Movva N, Sacks NC. To be or not to be a rare disease: An evaluation of prevalence estimates for cancers near the orphan status threshold. Poster O-008, National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, Washington, DC, October 25-27, 2026.

Beggs AH, Haselkorn T, Solomon F, Rumantir R, Bylsma LC, Vue S, Mitchell M, Kelsh M, Sacks NC, Graham RJ. Epidemiology of x-linked myotubular myopathy (XLMTM) in the United States using a machine learning model. Abstract/Poster 106S, Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, Orlando, FL, March 2026.

Broome C, Hausrath D, Jaworski J, Fernandez S, Edwards T,…, Bylsma L, Kelsh M,.., Mitchell M. Survival outcomes of patients with secondary hemophagocytic lymphohistiocytosis at two academic medical centers in the United States. Poster 905, Blood 146(Sup 1):6243; doi: 10.1182/blood-2025-6243. 67^th American Society of Hematology (ASH) Annual Meeting and Exposition, Orlando, FL, November 2025.

Movva N, Bylsma L, Suh M, Kelsh M, Van Valkenburgh H, Zaha R. 2025. Systematic literature review of bioavailability of characteristics, clinical presentations, and outcomes among women with pregnancies affected by fetal and neonatal alloimmune thrombocytopenia (FNAIT) and/or have anti-HPA-1a antibodies with no history of FNAIT. PROSPERO 2025:CRD420251153257. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251153257.

Johnson W, Covert K, Mitchell M, Kelsh M, Mangal B, Bose M, Dong K, Dao K-H. Real-world outcomes with available therapies in secondary hemophagocytic lymphohistiocytosis (sHLH): A natural history study with an embedded historical control arm. Poster 19, Histiocyte Society 41^st Annual Meeting, Seattle, WA, September 2025.

Shaw J, Hsu H, Tu H, Chia V, Aggarwal S, Carrigan G, Kelsh MA. Immortal time bias impacts time-to-time event outcomes in cohort with genomic testing. Abstract 6F-03, International Society for Pharmacoepidemiology (ISPE) 41^st Annual Meeting, Washington, DC, August 2025.

Kelsh M, Bylsma LC, Jiang X, Movva N, Sacks NC. To be an orphan disease or not to be: An evaluation of prevalence estimates for cancers near the orphan status threshold and implications for orphan drug planning. International Society for Pharmacoepidemiology, 40^th Annual Meeting, Berlin, Germany, August 2024.

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338; doi: 10.1007/s00520-022-06967-x. PMID: 35482126.

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer. Adv Ther 39(6):2778–2795; doi:10.1007/s12325-022-02141-1. PMID: 35430673.

McGrath LJ, Nielson C, Saul B, Breskin A, Yu Y, Nicolaisen SK, … Kelsh M, et al. 2021. Lessons learned using real-world data to emulate randomized trials: A case study of treatment effectiveness for newly diagnosed immune thrombocytopenia. Clin Pharmacol Ther 110(6):1570–1578; doi: 10.1002/cpt.2399. PMID: 34416023.

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315; doi: 10.1016/j.jgo.2020.06.018. PMID: 32624415.

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882; doi: 10.1016/j.clml.2020.06.007. PMID: 32792304.

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. 2020. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. Curr Med Res Opin 36(9):1519–1527; doi: 10.1080/03007995.2020.1801403. PMID: 32715807.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. 2020. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 28(9):4413–4424; doi: 10.1007/s00520-020-05295-2. PMID: 31919669.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478; doi: 10.1038/s41375-020-0770-8. PMID: 32094465.

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057; doi: 10.1002/cam4.2747. PMID: 31856410.

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186; doi: 10.1007/s13187-019-01638-8. PMID: 31656028.

Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M, et al. 2019. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: An observational cohort study using SEER Medicare data. Leuk Lymphoma 60(8):2015–2024; doi: 10.1080/10428194.2018.1555329. PMID: 30632830.